AG
NTLA icon

Aperio Group’s Intellia Therapeutics NTLA Stock Holding History

Aperio Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.15M Buy
21,163
+1,539
+8% +$55.9K ﹤0.01% 1521
2020
Q3 		$390K Sell
19,624
-748
-4% -$15.6K ﹤0.01% 1954
2020
Q2 		$428K Sell
20,372
-5,854
-22% -$99.5K ﹤0.01% 1842
2020
Q1 		$321K Buy
26,226
+14,756
+129% +$199K ﹤0.01% 1866
2019
Q4 		$168K Buy
+11,470
New +$160K ﹤0.01% 2220
2019
Q3 		– Sell
-5,044
Closed -$83K – 2602
2019
Q2 		$83K Buy
+5,044
New +$79.3K ﹤0.01% 2434

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

Aperio Group's NTLA Position: Q4 2020 in Review

Aperio Group increased its Intellia Therapeutics (NTLA) stake by 7.8% in Q4 2020, buying an estimated $55.9K and bringing the position to 21,163 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1521.

Aperio Group first reported a position in NTLA in Q2 2019 and has held it in 6 quarters since. 241 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

  • Aperio Group held 21,163 shares of Intellia Therapeutics worth $1.15M as of Q4 2020.
  • Aperio Group bought 1,539 Intellia Therapeutics shares in Q4 2020, an estimated $55.9K.
  • Intellia Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1521 holding.
  • Aperio Group first reported a position in Intellia Therapeutics in Q2 2019 and has held it in 6 quarters since.
  • 241 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.